New article published in Cancer Research about MTB
Read the latest article about the Jackson Laboratory’s Mouse Tumor Biology database (MTB) published in Cancer Research.
JAX has partnered with more than 20 cancer clinics to provide access to a wider range of patient-derived xenograft (PDX) cancer models at earlier passage numbers than any other PDX collection available today.
JAX PDX Resource: Development Process
More than 450 unique PDX oncology models from both treatment naive and resistant patients have been established in the highly immunodeficient NSG™ (005557) mouse strain. NSG™ mice engraft primary human tumors that, after low passage, retain the genetic and phenotypic heterogeneity typically seen in human cancers, offering a distinct advantage over other PDX hosts. This preclinical platform can predict the effectiveness of novel therapeutics to treat patients with cancer. We can conduct preclinical efficacy testing with customer-provided compounds at JAX using any of our PDX cancer models or ship PDX tumor-bearing mice to your facility.
PDX Live™ tumor models
Our collection of readily available, off-the-shelf PDX tumor-engrafted cohorts can help you put mice on study sooner, allowing rapid study turnaround and faster decision-making.
See our inventory of PDX Live™ tumor-bearing mice
A complete PDX cancer resource
These tumors types are available for engraftment in NSG™ mice for shipment of tumor-bearing mice to your facility or for execution of efficacy studies performed in our facility by our oncology scientists:
